[Adverse effects of cotrimoxazole in Spanish patients with AIDS and pneumonia caused by Pneumocystis carinii].
We retrospectively analyze the untoward effects due to cotrimoxazole (CMX) when this drug was used as initial therapy in 37 Spanish AIDS patients with Pneumocystis carinii pneumonia (PCP). A total of 46% of patients developed an adverse reaction, that was considered severe in 24.3% of cases, and prompted to stop CMX therapy in 10.8% of patients. The most frequent untoward effects were low white blood cells count (29.7%), skin rash (16.2%) and low platelet count (13.5%). The overall compliance and absence of undesirable effects to CMX seen in our patients, together with the well established clinical efficacy of this drug, allow us to recommend the use of CMX as initial therapy for Spanish AIDS patients with PCP.
Pérez-Cortés
S
S
Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cádiz.
Pérez-Pérez
M
M
Vergara de Campos
A
A
Torres
M
M
Lucero
M I
MI
Cifuentes
N
N
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology; D005076:Exanthema / Q000139:chemically induced* / Q000453:epidemiology / Q000208:ethnology; D005260:Female; D006801:Humans; D015994:Incidence; D007970:Leukopenia / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D013030:Spain / Q000453:epidemiology; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D015662:Trimethoprim, Sulfamethoxazole Drug Combination
Efectos indeseables del cotrimoxazol en pacientes españoles con SIDA y neumonía por Pneumocystis carinii.